Viridian Therapeutics Meets Endpoints in Late-Stage Veligrotug Trial for Thyroid Eye Disease

MT Newswires Live12-16

Viridian Therapeutics (VRDN) said Monday that a late-stage trial of candidate drug veligrotug met all of its primary and secondary endpoints for symptoms of chronic thyroid eye disease.

Viridian said about 56% of the trial's veligrotug-treated patients experienced a reduction in proptosis or the abnormal bulging of eyes, with a 2.34 mm mean reduction.

Additionally, 56% of the veligrotug population experienced a reduction in diplopia or double vision, with 32% achieving complete resolution, the company said.

The trial resulted in a 2.9-point mean reduction in inflammatory signs and symptoms from baseline, Viridian said.

Veligrotug was generally well-tolerated, with only mild adverse events, Viridian said.

Price: 21.20, Change: +3.35, Percent Change: +18.32

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment